Zoetis (ZTS)
(Delayed Data from NYSE)
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$190.03 USD
-0.96 (-0.50%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $189.97 -0.06 (-0.03%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Zacks News
The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Home Depot, Salesforce, Pfizer, Sony and Zoetis
Top Research Reports for Home Depot, salesforce & Pfizer
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), salesforce.com, inc. (CRM), and Pfizer Inc. (PFE).
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Zoetis (ZTS) earnings and revenues beat estimates in the second quarter of 2021. The company raised its financial guidance for 2021.
Zoetis (ZTS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 10.19% and 6.30%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q2 Earnings Due on Aug 5: REGN, MRNA, ZTS, ILMN
by Zacks Equity Research
Let us take a look at what is in store for some of the drug/biotech stocks, which are scheduled to report on Aug 5.
Why Earnings Season Could Be Great for Zoetis (ZTS)
by Zacks Equity Research
Zoetis (ZTS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Viatris (VTRS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger synergies when Viatris (VTRS) reports Q2 results.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2021 results.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases second-quarter 2021 results.
Eli Lilly (LLY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Higher demand for its growth drugs is likely to have offset generic competition for several other drugs and may have boosted Lilly's (LLY) second-quarter sales.
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Zoetis (ZTS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2
by Ekta Bagri
We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.
CORT or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
CORT vs. ZTS: Which Stock Is the Better Value Option?
Why Zoetis (ZTS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Zoetis (ZTS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study
by Zacks Equity Research
Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.
AcelRx (ACRX) Inks Agreement With Aguettant for Dzuveo in Europe
by Zacks Equity Research
AcelRx (ACRX) enters a licensing agreement for Dzuveo in Europe and an in-licensing agreement for two products in the United States.
TFF Pharmaceuticals (TFFP) Completes Enrollment in Phase I Study
by Zacks Equity Research
TFF Pharmaceuticals (TFFP) completes enrollment in the phase I study on tacrolimus inhalation powder and announces positive preliminary data.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Sigilon (SGTX) Down as FDA Places Hold on Hemophilia Study
by Zacks Equity Research
Sigilon (SGTX) stock declines as the FDA puts a clinical hold on its early/mid-stage hemophilia A study that was evaluating its lead candidate SIG-001.
Vaxart (VXRT) Enters an Agreement With Altesa for Antiviral
by Zacks Equity Research
Vaxart (VXRT) enters a licensing agreement with Altesa Biosciences, Inc., whereby the latter gets rights to develop, manufacture and commercialize vapendavir.
AMRX vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
AMRX vs. ZTS: Which Stock Is the Better Value Option?
AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition
by Zacks Equity Research
AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.